Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 7.8% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price fell 7.8% on Tuesday . The stock traded as low as $0.33 and last traded at $0.33. 39,393,920 shares were traded during mid-day trading, an increase of 28% from the average session volume of 30,856,506 shares. The stock had previously closed at $0.36.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Monday, December 23rd. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 9.8 %

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a market cap of $60.72 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The business’s 50 day moving average price is $0.23 and its 200 day moving average price is $0.37.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.